Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors
Patent No. EP3050882 (titled "Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors") was filed by Incyte on Mar 9, 2011. The application was issued on Jan 31, 2018.
Patent Summary
Selective JAK1 inhibitors for treating diseases associated with JAK1 overactivity, such as autoimmune disorders, allograft rejection, and cancers. The compounds are derived from a specific chemical structure and have selectivity for inhibiting JAK1 over other JAKs like JAK2, JAK3, and TYK2. This provides therapeutic advantages by avoiding unnecessary immunosuppression and anemia/bleeding side effects associated with less selective JAK inhibitors. The compounds can be administered alone or in combination therapies for treating diseases involving JAK1 overactivity.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3050882
- Application Number
- EP15195698A
- Filing Date
- Mar 9, 2011
- Status
- Revoked
- Jul 12, 2019
- Publication Date
- Jan 31, 2018
- External Links
- Slate, Register , Google Patents